Uncover key drivers, emerging technologies, and competitive movements shaping the malignant pleural effusion market from 2026–2035 with trusted insights from The Business Research Company
What long-term size projections exist for the Malignant Pleural Effusion Market covering 2026–2035?
The malignant pleural effusion market size has experienced significant growth in recent years. It is projected to increase from $4.73 billion in 2025 to $5.05 billion in 2026, at a compound annual growth rate (CAGR) of 6.8%. The expansion witnessed in the past can be attributed to the rising occurrence of metastatic cancers, the limited availability of curative treatment options, the reliance on repeated thoracentesis for managing symptoms, the growth in hospital-based cancer care, and the progressive adoption of pleurodesis techniques.
The malignant pleural effusion market size is projected to experience substantial growth over the upcoming years. It is anticipated to expand to $6.52 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.6%. This expected growth within the forecast period can be linked to several factors, including the global rise in cancer prevalence, innovations in pleural catheter technologies, a heightened focus on outpatient and home-based care models, enhanced accuracy in diagnostic imaging, and an increasing demand for treatments centered on improving quality of life. Prominent trends identified for this period include the wider adoption of indwelling pleural catheters for extended management, an escalating preference for minimally invasive pleural interventions, the greater integration of systemic cancer therapies into malignant pleural effusion management, an increased emphasis on symptom alleviation and palliative care strategies, and the expansion of imaging-guided diagnostic and therapeutic procedures.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp
Which Drivers Are Impacting The Competitive Landscape Of The Malignant Pleural Effusion Market?
An increase in lung cancer cases is projected to stimulate the expansion of the malignant pleural effusion market in the future. Lung cancer is characterized by the unchecked proliferation of abnormal cells within the lungs, forming masses that disrupt normal pulmonary function. The escalation of lung cancer instances is linked to smoking and tobacco consumption, as sustained exposure to hazardous chemicals in cigarettes damages lung tissue, induces genetic mutations, and fosters uncontrolled cancerous cell growth, thereby substantially elevating disease risk. Malignant pleural effusion signals advanced lung cancer progression by promoting tumor dissemination within the pleural cavity, leading to worsened respiratory health and a less favorable prognosis. For example, in January 2023, the American Cancer Society Facts and Figures, a US-based professional organizations company, reported an estimated 236,740 new lung and bronchus cancer cases in 2022 and 238,340 in 2023, with estimated deaths at 130,180 in 2022 and 127,070 in 2023. Consequently, the rising incidence of lung cancer is a key factor boosting the malignant pleural effusion market. Malignant Pleural Effusion Market Driver: Impact Of Improving Healthcare Infrastructure On The Market Due To Enhanced Diagnosis And Treatment Accessibility
What Leading Segments Are Studied In The Malignant Pleural Effusion Market?
The malignant pleural effusion market covered in this report is segmented –
1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter
2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy
3) By End Users: Hospitals, Ambulatory Clinics, Other End Users
Subsegments:
1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy
2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis
3) By Thoracic Drainage And Pleurodesis: Chemical Pleurodesis, Mechanical Pleurodesis
4) By Indwelling Pleural Catheter: Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter
Which Trends Are Guiding The Evolution Of The Malignant Pleural Effusion Market?
Major companies operating in the malignant pleural effusion market are directing their efforts towards developing innovative products, specifically fully-implantable automatic fluid-shunt devices, to enhance patient comfort and decrease the number of hospital visits. A fully-implantable automatic fluid-shunt device is a medical apparatus surgically placed within the body that autonomously drains surplus pleural fluid from the lungs into the abdomen or another region. This process helps to mitigate symptoms of breathlessness, lessen the requirement for repetitive hospital procedures, and elevate a patient’s quality of life. For instance, in October 2023, Pleural Dynamics, a US-based medical device company, launched its ACES Automatic Continuous Effusion Shunt System. This device incorporates a durable, flexible pump chamber implanted under the skin between the ribs, with one catheter positioned in the pleural space and another in the peritoneal space. With each breath taken by the patient, the internal pump extension undergoes compression and decompression between adjacent ribs, thereby propelling fluid from the pleural cavity to the abdomen where it is reabsorbed; the system also permits manual activation via an external compression extension. Key characteristics include a completely implantable design, no need for external drainage tubing or suction bottles, an automatic pumping function powered by breathing, a minimal hospital stay for implantation, and continuous symptom alleviation for recurrent effusions.
Which Major Firms Are Strengthening Their Position In The Malignant Pleural Effusion Market?
Major companies operating in the malignant pleural effusion market are Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc, Argon Medical Devices Inc, B Braun SE, Medtronic plc, Smiths Medical, Teleflex Incorporated, Cardinal Health Inc, Getinge AB, AngioDynamics Inc, Rocket Medical plc, Redax SpA, Atrium Medical Corporation, PolyMedicure Ltd, Troge Medical GmbH, Vygon SA, ICU Medical Inc, ConvaTec Group plc, Baxter International Inc
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report
Which Global Regions Are Shaping The Competitive Landscape Of The Malignant Pleural Effusion Market?
North America was the largest region in the malignant pleural effusion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Malignant Pleural Effusion Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=22047&type=smp
Browse Through More Reports Similar to the Global Malignant Pleural Effusion Market 2026, By The Business Research Company
Aortic Aneurysm Market Report 2026
https://www.thebusinessresearchcompany.com/report/aortic-aneurysm-global-market-report
Pulmonary Embolism Market Report 2026
https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report
Esophageal Cancer Market Report 2026
https://www.thebusinessresearchcompany.com/report/esophageal-cancer-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model